The ability of poliovirus to propagate in neuronal cells can be reduced by introducing appropriate nucleotide substitutions into the viral genome. Specific mutations scattered throughout the poliovirus genome yielded the live attenuated vaccine strains of poliovirus. Neuron-specific propagation deficits of the Sabin strains are partially encrypted within a confined region of the internal ribosomal entry site (IRES), which carries attenuating point mutations in all three serotypes. Recently, high levels of neurovirulence attenuation were achieved with genetically engineered polioviruses containing heterologous IRES elements. This is exemplified with poliovirus recombinants replicating under control of a human rhinovirus type 2 (HRV2) IRES element. We have carried out experiments delineating the genetic basis for neuronal IRES function. Neuronal dysfunction of the HRV2 IRES is determined mainly by IRES stem-loop domain V, the locus for attenuating point mutations within the Sabin strains. Neuronal incompetence associated with HRV2 IRES domain V is substantially more pronounced than that observed with the attenuating IRES point mutation of the Sabin serotype 1 vaccine strain. Mix-and-match recombination of polio and HRV2 IRES domain V suggests that the attenuation phenotype correlates with overall structural features rather than primary sequence. Our experiments have identified HEK 293 cells as a novel system for the study of neuron-specific replication phenotypes of poliovirus. This cell line, originally derived from embryonic human kidney, has recently been described to display neuronal characteristics. We report propagation properties in HEK 293 cells for poliovirus recombinants with attenuated neurovirulence in experimental animals that corroborate this observation.Poliovirus (PV), a positive-strand RNA virus of approximately 7,500 nucleotides (nt), is the prototypic member of the genus Enterovirus in the family Picornaviridae. PV is the causative agent of poliomyelitis, a paralytic condition complicating ϳ1% of all PV infections. The incidence of poliomyelitis has been drastically reduced since the introduction of two effective vaccines-the live attenuated (Sabin) strains and the formalininactivated (Salk) vaccine. Serial passage of wild-type (wt) PV in various culture systems yielded the serotype 1 and 3 Sabin strains, while serotype 2 is a naturally occurring variant with inherently reduced neurovirulence (48).It is generally assumed that the excellent safety record of the Sabin strains (the rate of vaccine-associated paralytic poliomyelitis [VAPP] is estimated at 0.14 per 1,000,000 doses) (60) is a direct reflection of tissue type-specific deficiencies that affect their propagation in the human central nervous system (CNS). Nevertheless, despite over 40 years of successful application, the molecular basis for neuroattenuation of the Sabin strains is not completely understood (16).Elucidation of the genomic sequences of PV type 1 (Sabin) [PV1(S)] (38) and PV3(S) (53, 58) and comparison to their wt progenitor...
Purpose: The toxicity and antitumor activity of regional intrathecal delivery of an oncolytic recombinant poliovirus, PVS-RIPO, was evaluated in rodent models of glioblastoma multiforme neoplastic meningitis. Experimental Design: To evaluate for toxicity, PVS-RIPO was administered into the spinal cord of transgenic mice that express the human poliovirus receptor, CD155, and into the intrathecal space of athymic rats without tumor. To evaluate efficacy, two different doses of PVS-RIPO were administered intrathecally 3 days after athymic rats were inoculated intrathecally with an aggressive human glioblastoma multiforme xenograft. Results: No clinical or histologic evidence of toxicity was found. In efficacy studies, median survival was increased by 174.47% from 8.5 days in the group treated with UV light-inactivated virus to 15 days in the rats treated with 1.0 Â 10 7 plaque-forming units (pfu) of PVS-RIPO (P < 0.0001).A similar increase in median survival was seen in the group receiving 1.0 Â 10 9 pfu PVS-RIPO (P < 0.0001); however, there was no statistically significant dose-response relationship (P = 0.345). In addition, 1 of 10 rats in lower-dose PVS-RIPO^treated group and 3 of 10 rats in higher-dose PVS-RIPO^treated group survived >60 days after tumor cell inoculation and had no evidence of residual tumor at autopsy. Conclusion: These results suggest that intrathecal treatment with PVS-RIPO may be useful for treatment of neoplastic meningitis in patients with glioblastoma multiforme and provides a rationale for clinical trials in this area.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.